What is the equity of Novacyt this year?
Novacyt has equity of 87.24 M GBP this year.
Novacyt Equity 2024
Novacyt Equity
87.24 M GBP
Ticker
ALNOV.PA
ISIN
FR0010397232
WKN
A12CFH
In 2024, Novacyt's equity was 87.24 M GBP, a -24.28% increase from the 115.22 M GBP equity in the previous year.
Novacyt Aktienanalyse
What does Novacyt do?
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Novacyt's Equity
Novacyt's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Novacyt's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Novacyt's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Novacyt's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Novacyt’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Novacyt stock
What was the equity of Novacyt compared to the previous year?
The equity of Novacyt has increased/decreased by -24.28% decreased compared to the previous year.
What impact does a high equity have on investors of Novacyt?
A high equity is advantageous for investors of Novacyt as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Novacyt?
A low equity can be a risk for investors of Novacyt, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Novacyt affect the company?
An increase in equity of Novacyt can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Novacyt affect the company?
A reduction in equity of Novacyt can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Novacyt?
Some factors that can affect the equity of Novacyt include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Novacyt so important for investors?
The equity of Novacyt is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Novacyt take to change the equity?
To change equity, Novacyt can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Novacyt pay?
Over the past 12 months, Novacyt paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novacyt is expected to pay a dividend of 0 GBP.
What is the dividend yield of Novacyt?
The current dividend yield of Novacyt is .
When does Novacyt pay dividends?
Novacyt pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novacyt?
Novacyt paid dividends every year for the past 0 years.
What is the dividend of Novacyt?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novacyt located?
Novacyt is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novacyt kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novacyt from 9/10/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Novacyt pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Novacyt in the year 2023?
In the year 2023, Novacyt distributed 0 GBP as dividends.
In which currency does Novacyt pay out the dividend?
The dividends of Novacyt are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novacyt
Our stock analysis for Novacyt Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
